Instytut Chorób Serca

Profesor wizytujący 

Prof. Stefan Anker, MD, PhD, FESC

 

stefan anker

 

Stefan D. Anker is Professor of (Tissue)Homeostasis in Cardiology & Metabolism (W3) at Charité BerlinStefan D. Anker is Professor of (Tissue)Homeostasis in Cardiology & Metabolism (W3) at Charité Berlin(from June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training inGermany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and hisPh.D. (1998) at National Heart & Lung Institute of Imperial College London. He was Professor ofCardiology & Cachexia Research (W2) at Charité (2002-14), and Professor of Innovative Clinical Trials(W3) in Göttingen (2014-17).

Dr. Anker has authored more than 1,000 articles (total citations: >97,000, h-index: 140, papers with ≥200citations: 103; source: Scopus, 2. May, 2021) and was named Highly Cited Researcher 2015–2020.For his work Dr. Anker has won several prizes, including the 2018 Copernicus Prize of German DFG &Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw /Poland.

Dr. Anker obtained a number of fellowships & grants, incl. from the NIH and the EU. He received grants forseveral IITs (3 currently running) from DZHK Germany & several industries.Dr. Anker was Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the board2012-2018. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14). He is founding Editor-in-Chief of the journal ESC Heart Failure (openaccess, IF-2019: 3.90). Dr. Anker worked in several ESC Guideline task forces (e.g. ESC HF GL 2012 &2016).

Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and WastingDisorders since 2008 (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of theJournal of Cachexia, Sarcopenia and Muscle since 2010 (JCSM, 2019-IF: 9.80, see www.jcsm.info).

Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairingseveral currently (EMPEROR-Preserved, FAIR-HF2, RESHAPE-HF2, RELIEVE-HF, REVIVE-HF,DIAMOND-HF, Fair-HFpEF) as well as in the past (incl. FAIR-HF, TIM-HF, ACT-ONE, AUGMENT-HF,BACH & EMPERIAL). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).